Abstract
More than 30% of people in the United States (US) are classified as obese, and over 50% are considered significantly overweight. Importantly, obesity is a risk factor not only for the development of metabolic syndrome but also for many cancers, including pancreatic ductal adenocarcinoma (PDAC). PDAC is the third leading cause of cancer-related death, and 5-year survival of PDAC remains around 9% in the U.S. Obesity is a known risk factor for PDAC. Metabolic control and bariatric surgery, which is an effective treatment for severe obesity and allows massive weight loss, have been shown to reduce the risk of PDAC. It is therefore clear that elucidating the connection between obesity and PDAC is important for the identification of a novel marker and/or intervention point for obesity-related PDAC risk. In this review, we discussed recent progress in obesity-related PDAC in epidemiology, mechanisms, and potential cancer prevention effects of interventions, including bariatric surgery with preclinical and clinical studies.
Original language | English (US) |
---|---|
Article number | 1284 |
Journal | Biomedicines |
Volume | 10 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2022 |
Bibliographical note
Funding Information:Funding: This research was funded by Eugene C. and Gail V. Sit Chair in Pancreatic and Gastrointestinal Cancer Research to M.Y. and NIH AG069819 to D.A.B.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords
- bariatric surgery
- obesity
- pancreatic cancer
- PDAC
PubMed: MeSH publication types
- Journal Article
- Review